{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:56:55Z","timestamp":1794283015647,"version":"4.9.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00613","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T04:43:32Z","timestamp":1588653812000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":87,"title":["Long-Lasting Rituximab-Induced Reduction of Specific\u2014But Not Total\u2014IgG4 in MuSK-Positive Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Mariapaola","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Spagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Napodano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Todi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Bartoccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Evoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2008.07.019","article-title":"B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.","volume":"204","author":"St\u00fcbgen","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases.","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients.","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","article-title":"IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.","volume":"1413","author":"Huijbers","year":"2018","journal-title":"Ann NY Acad Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease.","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis."},{"key":"B7","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity.","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","article-title":"MuSK myasthenia gravis monoclonal antibodies. Valency dictates pathogenicity.","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia.","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up.","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","article-title":"Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis.","volume":"74","author":"Robeson","year":"2017","journal-title":"JAMA Neurol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: A systematic review.","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. task force of the medical scientific advisory board of the myasthenia gravis foundation of America.","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis.","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity."},{"key":"B25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B26","year":"","journal-title":"Rituxan-FDA Prescribing Information, Side Effects and Uses."},{"key":"B27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece.","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.","volume":"84","author":"Keung","year":"2013","journal-title":"Neurol Neurosurg Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results.","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve."},{"key":"B30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.2012.06781.x","article-title":"Management challenges in muscle-specific tyrosine kinase myasthenia gravis.","volume":"1274","author":"Evoli","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B31","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients.","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med."},{"key":"B32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary.","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight."},{"key":"B34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis.","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.4049\/jimmunol.1300161","article-title":"What is and what should always have been: long-lived plasma cells induced by T-cell independent antigens.","volume":"190","author":"Bortnick","year":"2013","journal-title":"J. Immunol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4\u2212related systemic disease.","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine (Baltimore)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann. N Y Acad Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.","volume":"5","author":"Cort\u00e9s-Vicente","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/nyas.13562","article-title":"Rituximab in myasthenia gravis: a \u201cto be or not to be\u201d inhibitor of T cell function.","volume":"1413","author":"Marino","year":"2018","journal-title":"Ann N Y Acad Sci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00613\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T04:43:35Z","timestamp":1588653815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00613\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2020.00613"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00613","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2020.00613.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"article-number":"613"}}